M Ploug

Summary

Affiliation: Finsen Laboratory
Country: Denmark

Publications

  1. ncbi Structural analysis of the interaction between urokinase-type plasminogen activator and its receptor: a potential target for anti-invasive cancer therapy
    M Ploug
    Finsen Laboratory, Strandboulevarden 49, DK 2100 Copenhagen, Denmark
    Biochem Soc Trans 30:177-83. 2002
  2. ncbi Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist. Evidence for a composite ligand-binding site and a short interdomain separation
    M Ploug
    Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark
    Biochemistry 37:3612-22. 1998
  3. ncbi Cell-induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2-terminal domain of the urokinase receptor
    E Rønne
    Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark
    FEBS Lett 288:233-6. 1991
  4. ncbi The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants
    N Behrendt
    Finsen Laboratory, Righospitalet, Copenhagen, Denmark
    J Biol Chem 265:6453-60. 1990
  5. ncbi Cell-surface acceleration of urokinase-catalyzed receptor cleavage
    G Høyer-Hansen
    Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark
    Eur J Biochem 243:21-6. 1997
  6. ncbi Localization of the disulfide bonds in the NH2-terminal domain of the cellular receptor for human urokinase-type plasminogen activator. A domain structure belonging to a novel superfamily of glycolipid-anchored membrane proteins
    M Ploug
    Finsen Laboratory, Rigshospitalet Opg 86 21, Copenhagen, Denmark
    J Biol Chem 268:17539-46. 1993
  7. ncbi Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol
    M Ploug
    Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark
    J Biol Chem 266:1926-33. 1991
  8. ncbi Peptide-derived antagonists of the urokinase receptor. affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation
    M Ploug
    Finsen Laboratory, Rigshospitalet, Strandboulevarden 49, DK 2100 Copenhagen Ø, Denmark
    Biochemistry 40:12157-68. 2001
  9. ncbi Chemical modification of the urokinase-type plasminogen activator and its receptor using tetranitromethane. Evidence for the involvement of specific tyrosine residues in both molecules during receptor-ligand interaction
    M Ploug
    Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark
    Biochemistry 34:12524-34. 1995
  10. ncbi Identification of specific sites involved in ligand binding by photoaffinity labeling of the receptor for the urokinase-type plasminogen activator. Residues located at equivalent positions in uPAR domains I and III participate in the assembly of a composi
    M Ploug
    Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark
    Biochemistry 37:16494-505. 1998

Collaborators

Detail Information

Publications17

  1. ncbi Structural analysis of the interaction between urokinase-type plasminogen activator and its receptor: a potential target for anti-invasive cancer therapy
    M Ploug
    Finsen Laboratory, Strandboulevarden 49, DK 2100 Copenhagen, Denmark
    Biochem Soc Trans 30:177-83. 2002
    ..When tested in a chicken chorioallantoic membrane assay that was developed to quantify intravasation of human cells, this antagonist was able to reduce the intravasation of HEp-3 cancer cells by approx. 60%...
  2. ncbi Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist. Evidence for a composite ligand-binding site and a short interdomain separation
    M Ploug
    Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark
    Biochemistry 37:3612-22. 1998
    ..Since the receptor binding properties of the peptide antagonist closely mimic those of uPA itself, these two ligands presumably share coincident binding site in uPAR...
  3. ncbi Cell-induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2-terminal domain of the urokinase receptor
    E Rønne
    Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark
    FEBS Lett 288:233-6. 1991
    ....
  4. ncbi The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants
    N Behrendt
    Finsen Laboratory, Righospitalet, Copenhagen, Denmark
    J Biol Chem 265:6453-60. 1990
    ....
  5. ncbi Cell-surface acceleration of urokinase-catalyzed receptor cleavage
    G Høyer-Hansen
    Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark
    Eur J Biochem 243:21-6. 1997
    ..We propose that this mechanism plays a physiological role at specific sites with high local concentrations of uPA, thus adding another step to the complex regulation of this cascade reaction...
  6. ncbi Localization of the disulfide bonds in the NH2-terminal domain of the cellular receptor for human urokinase-type plasminogen activator. A domain structure belonging to a novel superfamily of glycolipid-anchored membrane proteins
    M Ploug
    Finsen Laboratory, Rigshospitalet Opg 86 21, Copenhagen, Denmark
    J Biol Chem 268:17539-46. 1993
    ..e. the membrane inhibitor of reactive lysis, Ly-6, and the remaining two domains of uPAR. However, an additional pair of cysteines present within these domains probably forms a fifth disulfide bond...
  7. ncbi Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol
    M Ploug
    Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark
    J Biol Chem 266:1926-33. 1991
    ..A similar proteolytic processing has been reported for other proteins that are linked to the plasma membrane by a glycosyl-phosphatidylinositol membrane anchor...
  8. ncbi Peptide-derived antagonists of the urokinase receptor. affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation
    M Ploug
    Finsen Laboratory, Rigshospitalet, Strandboulevarden 49, DK 2100 Copenhagen Ø, Denmark
    Biochemistry 40:12157-68. 2001
    ..These data imply that design of small organic molecules mimicking the binding determinants of this 9-mer peptide antagonist may have a potential application in combination therapy for certain types of cancer...
  9. ncbi Chemical modification of the urokinase-type plasminogen activator and its receptor using tetranitromethane. Evidence for the involvement of specific tyrosine residues in both molecules during receptor-ligand interaction
    M Ploug
    Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark
    Biochemistry 34:12524-34. 1995
    ....
  10. ncbi Identification of specific sites involved in ligand binding by photoaffinity labeling of the receptor for the urokinase-type plasminogen activator. Residues located at equivalent positions in uPAR domains I and III participate in the assembly of a composi
    M Ploug
    Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark
    Biochemistry 37:16494-505. 1998
    ..In addition, these data suggest that the assembly of the composite ligand binding site in uPAR may resemble the homophilic interdomain dimerization of kappa-bungarotoxin, a structural homologue of the Ly-6/uPAR domain family...
  11. ncbi Rational targeting of the urokinase receptor (uPAR): development of antagonists and non-invasive imaging probes
    M C Kriegbaum
    Finsen Laboratory, Copenhagen Biocenter, Rigshospitalet, Copenhagen, Denmark
    Curr Drug Targets 12:1711-28. 2011
    ..In this review, we will discuss recent advances in our perception of the structure-function relationships of uPAR ligation and how these may assist translational research in preclinical intervention studies of uPAR function...
  12. ncbi Glycosylation profile of a recombinant urokinase-type plasminogen activator receptor expressed in Chinese hamster ovary cells
    M Ploug
    Finsen Laboratory, Rigshospitalet, Strandboulevarden 49, DK 2100 Copenhagen O, Denmark
    J Biol Chem 273:13933-43. 1998
    ..uPAR preparations devoid of carbohydrate on domain I exhibited altered binding kinetics toward uPA (a 4-6-fold increase in Kd) as assessed by real time biomolecular interaction analysis...
  13. ncbi Plasminogen-independent initiation of the pro-urokinase activation cascade in vivo. Activation of pro-urokinase by glandular kallikrein (mGK-6) in plasminogen-deficient mice
    K List
    The Finsen Laboratory, Rigshospitalet, Strandboulevarden 49, DK 2100 Copenhagen O, Denmark
    Biochemistry 39:508-15. 2000
    ..Since this kallikrein is expressed in a number of tissues and also occurs in plasma, it can also be considered a candidate for a physiological pro-uPA activator in other locations...
  14. ncbi The murine receptor for urokinase-type plasminogen activator is primarily expressed in tissues actively undergoing remodeling
    H Solberg
    The Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark
    J Histochem Cytochem 49:237-46. 2001
    ..In Lewis lung carcinoma, uPAR immunoreactivity was found in the tumor cells of the primary tumor and in lung metastases. (J Histochem Cytochem 49:237-246, 2001)..
  15. ncbi The urokinase receptor and its structural homologue C4.4A in human cancer: expression, prognosis and pharmacological inhibition
    B Jacobsen
    Finsen Laboratory, Rigshospitalet, Copenhagen Biocenter, Copenhagen, Denmark
    Curr Med Chem 15:2559-73. 2008
    ..This review will evaluate structural-functional and disease-related aspects of uPAR and C4.4A with a view to possible pharmacological targeting strategies for therapy and for non-invasive bioimaging...
  16. ncbi Identification and characterization of the murine cell surface receptor for the urokinase-type plasminogen activator
    H Solberg
    Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark
    Eur J Biochem 205:451-8. 1992
    ..abstract truncated at 400 words)..
  17. ncbi Structural requirements for glycosyl-phosphatidylinositol-anchor attachment in the cellular receptor for urokinase plasminogen activator
    L B Møller
    Institute of Microbiology, University of Copenhagen, Denmark
    Eur J Biochem 208:493-500. 1992
    ....